Quick Answer
BIOLIFE SOLUTIONS INC reported Total Revenue of $11.02 million for fiscal year 2017.
BIOLIFE SOLUTIONS INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$4.59M +77.2% |
-$20.18M +70.3% |
-$68.00M +51.4% |
-$139.81M -1469.4% |
-$8.91M -549.2% |
$1.98M +219.7% |
| Diluted EPS | -$0.10 +77.3% |
-$0.44 +71.6% |
-$1.55 +52.3% |
-$3.25 -1313.0% |
-$0.23 -283.3% |
-$0.06 +33.3% |
| Total Assets | $405.88M +1.6% |
$399.49M -3.2% |
$412.71M -8.3% |
$450.23M -18.8% |
$554.29M +136.0% |
$234.83M +388.5% |
| Cash and Equivalents | $33.04M -63.9% |
$91.54M +228.1% |
$27.90M +43.5% |
$19.44M -72.2% |
$69.86M -22.7% |
$90.40M +184.1% |
| Long-Term Debt | $0.00 -100.0% |
$5.00M -71.5% |
$17.56M -26.2% |
$23.79M +274.5% |
$6.35M +869.9% |
$655.0K |
| Stockholders Equity | $371.89M +6.6% |
$348.91M +3.3% |
$337.66M -7.3% |
$364.19M -23.8% |
$478.05M +133.8% |
$204.43M +5566.0% |
| R&D Expense | $7.57M +59.3% |
$4.75M -13.9% |
$5.51M -36.4% |
$8.67M -26.6% |
$11.82M +75.9% |
$6.72M +112.1% |
| Operating Income | -$16.60M -270.8% |
-$4.48M +74.0% |
-$17.20M -190.5% |
-$5.92M +83.2% |
-$35.16M -463.4% |
-$6.24M -2736.8% |
| Gross Profit | $62.12M +24.0% |
$50.10M +21.2% |
$41.32M | — | — | — |
| Shares Outstanding | 48.20M +2.8% |
46.91M +3.9% |
45.17M +5.5% |
42.83M +2.4% |
41.82M +26.6% |
33.04M +76.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2017 | $2.96M | +38.8% | +15.9% |
| Net Income | September 30, 2025 | $621.0K | +136.5% | +103.9% |
| Diluted EPS | September 30, 2025 | $0.01 | +125.0% | +103.0% |
| Total Assets | September 30, 2025 | $392.08M | +2.7% | +1.3% |
| Cash and Equivalents | September 30, 2025 | $29.48M | +23.0% | -7.6% |
| Long-Term Debt | September 30, 2025 | $0.00 | -100.0% | — |
| Stockholders Equity | September 30, 2025 | $353.74M | +8.7% | +1.9% |
| R&D Expense | September 30, 2025 | $2.71M | +43.1% | -0.4% |
| Operating Income | September 30, 2025 | -$89.0K | +78.7% | +99.5% |
| Gross Profit | September 30, 2019 | $4.52M | +22.6% | -4.7% |
| Shares Outstanding | September 30, 2025 | 47.97M | +3.8% | +0.3% |
- BIOLIFE SOLUTIONS INC reported Total Revenue of $11.02 million for fiscal year 2017.
- BIOLIFE SOLUTIONS INC showed an increase of +34.0% in Total Revenue compared to the prior fiscal year.
- BIOLIFE SOLUTIONS INC reported Net Income of -$4.59 million for fiscal year 2025.
- BIOLIFE SOLUTIONS INC showed an increase of +77.2% in Net Income compared to the prior fiscal year.
- BIOLIFE SOLUTIONS INC reported Diluted EPS of $0.10 per share (loss) for fiscal year 2025.
- BIOLIFE SOLUTIONS INC showed an increase of +77.3% in Diluted EPS compared to the prior fiscal year.
- BIOLIFE SOLUTIONS INC reported Total Assets of $405.88 million for fiscal year 2025.
- BIOLIFE SOLUTIONS INC showed an increase of +1.6% in Total Assets compared to the prior fiscal year.
- BIOLIFE SOLUTIONS INC reported Cash and Equivalents of $33.04 million for fiscal year 2025.
- BIOLIFE SOLUTIONS INC showed a decrease of -63.9% in Cash and Equivalents compared to the prior fiscal year.
- BIOLIFE SOLUTIONS INC reported Long-Term Debt of $0.00 for fiscal year 2025.
- BIOLIFE SOLUTIONS INC showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- BIOLIFE SOLUTIONS INC reported Stockholders Equity of $371.89 million for fiscal year 2025.
- BIOLIFE SOLUTIONS INC showed an increase of +6.6% in Stockholders Equity compared to the prior fiscal year.
- BIOLIFE SOLUTIONS INC reported R&D Expense of $7.57 million for fiscal year 2025.
- BIOLIFE SOLUTIONS INC showed an increase of +59.3% in R&D Expense compared to the prior fiscal year.
- BIOLIFE SOLUTIONS INC reported Operating Income of -$16.60 million for fiscal year 2025.
- BIOLIFE SOLUTIONS INC showed a decrease of -270.8% in Operating Income compared to the prior fiscal year.
- BIOLIFE SOLUTIONS INC reported Gross Profit of $62.12 million for fiscal year 2025.
- BIOLIFE SOLUTIONS INC showed an increase of +24.0% in Gross Profit compared to the prior fiscal year.
- BIOLIFE SOLUTIONS INC reported Shares Outstanding of 48.20 million shares for fiscal year 2025.
- BIOLIFE SOLUTIONS INC showed an increase of +2.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: